Major surgery within  weeks before the first dose of cabozantinib; complete wound healing from major surgery must have occurred  month before the first dose of cabozantinib; minor surgery (including uncomplicated tooth extractions) is allowed if it occurred  days before the first dose of cabozantinib with complete wound healing at least  days before the first dose of cabozantinib; subjects with clinically relevant ongoing complications from prior surgery are not eligible
Major surgery within  weeks before the first dose of study treatment. Complete wound healing from major surgery must have occurred  month before the first dose of study treatment. Minor surgery (including uncomplicated tooth extractions) within  days before the first dose of study treatment with complete wound healing at least  days before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible
Other clinically significant disorders such as:\r\n* Active infection requiring systemic treatment within  days before the first dose of study treatment; participants with HIV infection will be eligible provided they meet the criteria; participants with known hepatitis B infection should be screened for active disease prior to study participation; participants with known hepatitis C infection must not be actively receiving treatment for the infection\r\n* Serious non-healing wound/ulcer/bone fracture within  days before the first dose of study treatment\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within  days before the first dose of study treatment\r\n* History of major surgery as follows:\r\n** Major surgery within  months of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications\r\n** Minor surgery within  month of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications\r\n* In addition, complete wound healing from prior surgery must be confirmed at least  days before the first dose of cabozantinib irrespective of the time from surgery
Other clinically significant disorders such as: i. active infection requiring systemic antibiotic treatment within  days before the first dose of study treatment ii. serious non-healing wound/ulcer/bone fracture within  days before the first dose of study treatment iii. history of organ transplant iv. concurrent uncompensated hypothyroidism or thyroid dysfunction (thyroid-stimulating hormone [TSH] above ) within  days before the first dose of study treatment v. major surgery within  weeks before the first dose of study treatment. Complete wound healing from major surgery must have occurred  month before the first dose of study treatment. Minor surgery within  days before the first dose of study treatment with complete wound healing at least  days before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.
Major surgery within  weeks before the first dose of study treatment; complete wound healing from major surgery must have occurred  month before the first dose of study treatment; minor surgery (including uncomplicated tooth extractions) within  days before the first dose of study treatment with complete wound healing at least  days before the first dose of study treatment; all clinically relevant ongoing complications from prior surgery should be resolved before the first dose of study treatment
Major surgery within  weeks before the first dose of study treatment; complete wound healing from major surgery must have occurred  month before the first dose of study treatment; minor surgery (including uncomplicated tooth extractions) within  days before the first dose of study treatment with complete wound healing at least  days before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior surgery are not eligible
History of major surgery as follows:\r\n* Major surgery within  months of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications\r\n* Minor surgery within  months of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications
In addition, complete wound healing from prior surgery must be confirmed at least  days before the first dose of cabozantinib irrespective of the time from surgery
Other clinically significant disorders such as:\r\n* Active infection requiring systemic treatment within  days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within  days before the first dose of study treatment\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within  days before the first dose of study treatment\r\n* History of major surgery as follows:\r\n** Major surgery within  months of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications\r\n** Minor surgery within  month of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications\r\n* In addition, complete wound healing from prior surgery must be confirmed at least  days before the first dose of cabozantinib irrespective of the time from surgery
Major surgery within  weeks before the first dose of study treatment; complete wound healing from major surgery must have occurred  month before the first dose of study treatment; minor surgery (including uncomplicated tooth extractions) within  days before the first dose of study treatment with complete wound healing at least  days before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior surgery are not eligible
The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\r\n* Cardiovascular disorders including\r\n** Congestive heart failure (CHF): New York Heart Association (NYHA) Class III (moderate) or Class IV (severe) at the time of screening\r\n** Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) >  mm Hg systolic, or >  mm Hg diastolic despite optimal antihypertensive treatment within  days of the first dose of study treatment\r\n** Any history of congenital long QT syndrome\r\n** Any of the following within  months before the first dose of study treatment:\r\n*** Unstable angina pectoris\r\n*** Clinically-significant cardiac arrhythmias\r\n*** Stroke (including transient ischemic attack (TIA), or other ischemic event)\r\n*** Myocardial infarction\r\n*** Thromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous filter (e.g. vena cava filter) are not eligible for this study)\r\n* Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including:\r\n** Any of the following within  days before the first dose of study treatment\r\n*** Intra-abdominal tumor/metastases invading GI mucosa\r\n*** Active peptic ulcer disease,\r\n*** Inflammatory bowel disease (including ulcerative colitis and Crohns disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis\r\n*** Malabsorption syndrome\r\n** Any of the following within  months before the first dose of study treatment:\r\n*** Abdominal fistula\r\n*** Gastrointestinal perforation\r\n*** Bowel obstruction or gastric outlet obstruction\r\n*** Intra-abdominal abscess. Note: Complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than  months before the first dose of study treatment\r\n* Other disorders associated with a high risk of fistula formation including percutaneous endoscopic gastrostomy (PEG) tube placement within  months before the first dose of study therapy\r\n* Other clinically significant disorders such as:\r\n** Serious active infection requiring systemic treatment within  days before the first dose of study treatment\r\n** Serious non-healing wound/ulcer/bone fracture within  days before the first dose of study treatment\r\n** History of organ transplant\r\n** Concurrent uncompensated hypothyroidism or thyroid dysfunction within  days before the first dose of study treatment\r\n** History of surgery as follows:\r\n*** Subjects having undergone recent resection or biopsy of an intracranial tumor will be eligible as long as all of the following conditions apply: First dose of cabozantinib occurs at least  days after surgery, and the subject has recovered from the effects of surgery\r\n*** Other minor surgery within  days of the first dose of cabozantinib if there were no wound healing complications. If there is evidence of wound dehiscence, subjects will be eligible for trial after a minimum of  months after surgery to the first dose of cabozantinib, provided complete wound healing is confirmed at least  days before the first dose of cabozantinib\r\n*** Other major surgery within  months of the first dose of cabozantinib if there were no wound healing complications; if there is evidence of wound dehiscence, subjects will be eligible for trial after a minimum of  months after surgery to the first dose of cabozantinib, provided complete wound healing in confirmed at least  days before the first dose of cabozantinib
The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\r\n* Cardiovascular disorders including\r\n** Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening\r\n** Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) >  mm Hg systolic, or >  mm Hg diastolic despite optimal antihypertensive treatment within  days of the first dose of study treatment\r\n** Any history of congenital long QT syndrome\r\n** Any of the following within  months before the first dose of study treatment:\r\n*** Unstable angina pectoris\r\n*** Clinically-significant cardiac arrhythmias\r\n*** Stroke (including transient ischemic attack [TIA], or other ischemic event)\r\n*** Myocardial infarction\r\n*** Thromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous filter [e.g. vena cava filter] are not eligible for this study)\r\n* Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including:\r\n** Any of the following within  days before the first dose of study treatment\r\n*** Intra-abdominal tumor/metastases invading GI mucosa\r\n*** Active peptic ulcer disease\r\n*** Inflammatory bowel disease (including ulcerative colitis and Crohns disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis\r\n*** Malabsorption syndrome\r\n** Any of the following within  months before the first dose of study treatment:\r\n*** Abdominal fistula\r\n*** Gastrointestinal perforation\r\n*** Bowel obstruction or gastric outlet obstruction\r\n*** Intra-abdominal abscess; Note: complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than  months before the first dose of study treatment\r\n* Other disorders associated with a high risk of fistula formation including percutaneous endoscopic gastrostomy (PEG) tube placement within  months before the first dose of study therapy\r\n* Other clinically significant disorders such as:\r\n** Active infection requiring systemic treatment within  days before the first dose of study treatment\r\n** Serious non-healing wound/ulcer/bone fracture within  days before the first dose of study treatment\r\n** History of organ transplant\r\n** Concurrent uncompensated hypothyroidism or thyroid dysfunction within  days before the first dose of study treatment\r\n** History of major surgery as follows:\r\n*** Major surgery within  months of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications\r\n*** Minor surgery within  months of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications; in addition complete wound healing from prior surgery must be confirmed at least  days before the first dose of cabozantinib irrespective of the time from surgery
Major surgery within  weeks before the first dose of study treatment; complete wound healing from major surgery must have occurred  month before the first dose of study treatment; minor surgery (including uncomplicated tooth extractions) within  days before the first dose of study treatment with complete wound healing at least  days before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior surgery are not eligible
Other clinically significant disorders such as:\r\n* Active uncontrolled infection requiring intravenous systemic treatment within  days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within  days before the first dose of study treatment\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within  days before the first dose of study treatment\r\n* History of major surgery as follows:\r\n** Major surgery within  months of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications\r\n** Minor surgery within  month of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications\r\n*** In addition, complete wound healing from prior surgery must be confirmed at least  days before the first dose of cabozantinib irrespective of the time from surgery
The patient may not have uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\r\n* Cardiovascular disorders including:\r\n** Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening\r\n** Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) >  mmHg systolic, or >  mmHg diastolic despite optimal antihypertensive treatment within  days of the first dose of study treatment\r\n** Any history of congenital long QT syndrome\r\n** Any of the following within  weeks before the first dose of study treatment:\r\n*** Unstable angina pectoris\r\n*** Clinically-significant cardiac arrhythmias\r\n*** Stroke (including transient ischemic attack [TIA], or other ischemic event)\r\n*** Myocardial infarction\r\n*** Thromboembolic event requiring therapeutic anticoagulation (Note: patients with a venous filter [e.g. vena cava filter] are not eligible for this study)\r\n* Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including:\r\n** Any of the following within  days before the first dose of study treatment\r\n*** Intra-abdominal tumor/metastases invading GI mucosa\r\n*** Active peptic ulcer disease\r\n*** Inflammatory bowel disease (including ulcerative colitis and Crohns disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis\r\n*** Malabsorption syndrome\r\n** Any of the following within  weeks before the first dose of study treatment:\r\n*** Abdominal fistula\r\n*** Gastrointestinal perforation\r\n*** Intra-abdominal abscess; Note: complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more that  weeks before the first dose of study treatment\r\n*** Bowel obstruction or gastric outlet obstruction\r\n* Other clinically significant disorders such as:\r\n** Serious non-healing wound/ulcer/bone fracture within  days before the first dose of study treatment\r\n** History of organ transplant\r\n** Concurrent uncompensated hypothyroidism or thyroid dysfunction within  days before the first dose of study treatment\r\n** History of major surgery as follows:\r\n*** Major surgery in past  weeks of the first dose of cabozantinib if there were no wound healing complications or within  weeks of the first dose of cabozantinib if there were wound complications\r\n*** Minor surgery within  weeks of the first dose of cabozantinib if there were no wound healing complications or within  weeks of the first dose of cabozantinib if there were wound complications\r\n*** In addition, complete wound healing from prior surgery must be confirmed at least  days before the first dose of cabozantinib irrespective of the time from surgery\r\n** Active infection requiring systemic treatment within  days before the first dose of study treatment
The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\r\n* Cardiovascular disorders including:\r\n** Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening\r\n** Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) >  mm Hg systolic, or >  mm Hg diastolic despite optimal antihypertensive treatment (BP must be controlled at screening)\r\n** Any history of congenital long QT syndrome\r\n** Any of the following within  months before the first dose of study treatment:\r\n*** Unstable angina pectoris\r\n*** Clinically-significant cardiac arrhythmias\r\n*** Stroke (including transient ischemic attack [TIA], or other ischemic event)\r\n*** Myocardial infarction\r\n* Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including:\r\n** Any of the following within  days before the first dose of cabozantinib:\r\n*** Active peptic ulcer disease\r\n*** Active inflammatory bowel disease (including ulcerative colitis and Crohns disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis\r\n*** Active malabsorption syndrome\r\n** Any of the following within  months before the first dose of study treatment:\r\n*** Abdominal fistula\r\n*** Gastrointestinal perforation\r\n*** Bowel obstruction or gastric outlet obstruction\r\n*** Intra-abdominal abscess; Note: complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than  months ago\r\n*** Other disorders associated with a high risk of fistula formation including percutaneous endoscopic gastrostomy (PEG) tube placement within  months before the first dose of study therapy\r\n* Other clinically significant disorders such as:\r\n** No active systemic infection requiring parenteral antibiotics\r\n** Serious non-healing wound/ulcer/bone fracture within  days before the first dose of study treatment\r\n** History of organ transplant\r\n** Concurrent uncompensated hypothyroidism or thyroid dysfunction within  days before the first dose of study treatment\r\n** History of major surgery as follows:\r\n*** Major surgery within  months of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications\r\n*** Minor surgery within  months of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications\r\n*** In addition, complete wound healing from prior surgery must be confirmed at least  days before the first dose of cabozantinib irrespective of the time from surgery
If most recent therapy was surgery, participants must be at least  days out from definitive surgery with no active wound healing complications
History of major/minor surgery as follows:\r\n* Major surgery within  months of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications\r\n* Minor surgery within  month of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications; in addition complete wound healing from prior surgery must be confirmed at least  days before the first dose of cabozantinib irrespective of the time from surgery
The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\r\n* Cardiovascular disorders including\r\n** Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening\r\n** Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) >  mm Hg systolic, or >  mm Hg diastolic despite optimal antihypertensive treatment (BP must be controlled at screening)\r\n** Any history of congenital long QT syndrome\r\n** Any of the following within  months before the first dose of study treatment:\r\n*** Unstable angina pectoris\r\n*** Clinically-significant cardiac arrhythmias\r\n*** Stroke (including transient ischemic attack [TIA], or other ischemic event)\r\n*** Myocardial infarction\r\n*** Thromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous filter [e.g. vena cava filter] are not eligible for this study)\r\n* Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including:\r\n** Any of the following within  days before the first dose of study treatment \r\n*** Intra-abdominal tumor/metastases invading GI mucosa\r\n*** Active peptic ulcer disease\r\n*** Inflammatory bowel disease (including ulcerative colitis and Crohns disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis\r\n*** Malabsorption syndrome\r\n** Any of the following within  months before the first dose of study treatment:\r\n*** History of abdominal fistula\r\n*** Gastrointestinal perforation\r\n*** Bowel obstruction or gastric outlet obstruction\r\n*** Intra-abdominal abscess; Note: complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than  months ago\r\n* Other disorders associated with a high risk of fistula formation including percutaneous endoscopic gastrostomy (PEG) tube placement within  months before the first dose of study therapy or concurrent evidence of intraluminal tumor involving the trachea and esophagus\r\n* Other clinically significant disorders such as:\r\n** Active infection requiring intravenous treatment within  days of starting protocol treatment\r\n** Serious non-healing wound/ulcer/bone fracture within  days before the first dose of study treatment\r\n** History of organ transplant\r\n** Concurrent uncompensated hypothyroidism or thyroid dysfunction within  days before the first dose of study treatment\r\n** History of major surgery as follows:\r\n*** Major surgery within  months of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications\r\n*** Minor surgery within  months of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications\r\n*** In addition, complete wound healing from prior surgery must be confirmed at least  days before the first dose of cabozantinib irrespective of the time from surgery
The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\r\n* Cardiovascular disorders including:\r\n** Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening\r\n** Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) >  mm Hg systolic, or >  mm Hg diastolic despite optimal antihypertensive treatment within  days before the first dose of study treatment\r\n** Any history of congenital long QT syndrome\r\n** Any of the following within  months before the first dose of study treatment:\r\n*** Unstable angina pectoris\r\n*** Clinically-significant cardiac arrhythmias\r\n*** Stroke (including transient ischemic attack [TIA], or other ischemic event)\r\n*** Myocardial infarction\r\n*** Thromboembolic event requiring therapeutic anticoagulation (note: subjects with a venous filter [e.g. vena cava filter] are not eligible for this study)\r\n* Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including:\r\n** Any of the following within  days before the first dose of study treatment:\r\n*** Intra-abdominal tumor/metastases invading GI mucosa\r\n*** Active peptic ulcer disease\r\n*** Inflammatory bowel disease (including ulcerative colitis and Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis\r\n*** Malabsorption syndrome\r\n** Any of the following within  months before the first dose of study treatment:\r\n*** Abdominal fistula\r\n*** Gastrointestinal perforation\r\n*** Bowel obstruction or gastric outlet obstruction\r\n*** Intra-abdominal abscess; note: complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than  months before the first dose of study treatment\r\n** Other disorders associated with a high risk of fistula formation including percutaneous endoscopic gastrostomy (PEG) tube placement within  months before the first dose of study therapy \r\n* Other clinically significant disorders such as:\r\n** Active infection requiring systemic treatment within  days before the first dose of study treatment\r\n** Serious non-healing wound/ulcer/bone fracture within  days before the first dose of study treatment\r\n** History of organ transplant\r\n** Concurrent uncompensated hypothyroidism or thyroid dysfunction within  days before the first dose of study treatment\r\n** History of major surgery as follows:\r\n*** Major surgery within  months of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications\r\n*** Minor surgery within  months of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications\r\n*** Complete wound healing from prior surgery must be confirmed at least  days before the first dose of cabozantinib irrespective of the time from surgery
Other clinically significant disorders such as:\r\n* Severe active infection requiring systemic treatment within  days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within  days before the first dose of study treatment\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within  days before the first dose of study treatment (for asymptomatic patients with an elevated thyroid stimulating hormone [TSH], thyroid replacement may be initiated if clinically indicated without delaying the start of study treatment)\r\n* History of major surgery as follows:\r\n** Major surgery within  months of the first dose of cabozantinib; however, if there were no wound healing complications, patients with rapidly growing aggressive cancers, may start as soon as  weeks if wound has completely healed post-surgery\r\n** Minor surgery within  month of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications excluding core biopsies and Mediport placement\r\n* In addition, complete wound healing from prior surgery must be confirmed at least  days before the first dose of cabozantinib irrespective of the time from surgery
Subject has history of major surgery as follows:\r\n* Major surgery within  months of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications\r\n* Minor surgery within  months of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications\r\n* In addition complete wound healing from prior surgery must be confirmed at least  days before the first dose of cabozantinib irrespective of the time from surgery
History of major surgery as follows:\r\n* Major surgery within  months of the first dose of cabozantinib; major surgery within  months of the first dose of cabozantinib if there are complications related to wound healing\r\n* Minor surgery within  month of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications (particularly when associated with delayed or incomplete healing) within  days; Note: complete healing following abdominal surgery must be confirmed prior to initiating treatment with cabozantinib even if surgery occurred more than  days ago
The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions: \r\n* Cardiovascular disorders including: \r\n** Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening \r\n** Concurrent uncontrolled hypertension defined as sustained BP >  mm Hg systolic, or >  mm Hg diastolic despite optimal antihypertensive treatment within  days of the first dose of study treatment \r\n** Any history of congenital long QT syndrome \r\n** Any of the following within  months before the first dose of study treatment: \r\n*** Unstable angina pectoris \r\n*** Clinically-significant cardiac arrhythmias \r\n*** Stroke (including transient ischemic attack [TIA], or other ischemic event) \r\n*** Myocardial infarction \r\n*** Thromboembolic event requiring therapeutic anticoagulation (note: subjects with a venous filter [e.g. vena cava filter] are not eligible for this study)\r\n* Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including: \r\n** Any of the following within  days before the first dose of study treatment\r\n*** Intra-abdominal tumor/metastases invading GI mucosa \r\n*** Active peptic ulcer disease\r\n*** Inflammatory bowel disease (including ulcerative colitis and Crohns disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis \r\n*** Malabsorption syndrome \r\n** Any of the following within  months before the first dose of study treatment: \r\n*** Abdominal fistula \r\n*** Gastrointestinal perforation \r\n*** Bowel obstruction or gastric outlet obstruction \r\n*** Intra-abdominal abscess; note: complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than  months before the first dose of study treatment\r\n* Other disorders associated with a high risk of fistula formation including percutaneous endoscopic gastrostomy (PEG) tube placement within  months before the first dose of study therapy \r\n* Other clinically significant disorders such as: \r\n** Serious non-healing wound/ulcer/bone fracture within  days before the first dose of study treatment \r\n** History of organ transplant, including allogeneic bone marrow transplant \r\n** Concurrent uncompensated hypothyroidism or thyroid dysfunction within  days before the first dose of study treatment \r\n** History of major surgery as follows:\r\n*** Major surgery within  months of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications \r\n*** Minor surgery within  month of the first dose of cabozantinib if there were no wound healing complications or within  months of the first dose of cabozantinib if there were wound complications \r\n** In addition, complete wound healing from prior surgery must be confirmed at least  days before the first dose of cabozantinib irrespective of the time from surgery
GI surgery (particularly when associated with delayed or incomplete healing) within  days; Note: complete healing following abdominal surgery must be confirmed prior to initiating treatment with cabozantinib even if surgery occurred more than  days ago
Other clinically significant disorders such as:\r\n* Active infection requiring systemic treatment within  days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within  days before the first dose of study treatment\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within  days before the first dose of study treatment\r\n* Major surgery (eg, thoracotomy, removal or biopsy of brain metastasis) within  months before week  day ; complete wound healing from major surgery must have occurred  month before week  day  and from minor surgery (eg, simple excision, tooth extraction) at least  days before week  day ; subjects with clinically relevant ongoing complications from prior surgery are not eligible
